Published in Amyotroph Lateral Scler on November 12, 2010
Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J Med Chem (2011) 1.22
Moving forward in clinical trials for ALS: motor neurons lead the way please. Drug Discov Today (2013) 0.89
Recent progress in the discovery of small molecules for the treatment of amyotrophic lateral sclerosis (ALS). Beilstein J Org Chem (2013) 0.87
Cyclohexane 1,3-diones and their inhibition of mutant SOD1-dependent protein aggregation and toxicity in PC12 cells. Bioorg Med Chem (2011) 0.87
Chiral cyclohexane 1,3-diones as inhibitors of mutant SOD1-dependent protein aggregation for the treatment of ALS. ACS Med Chem Lett (2012) 0.81
Exposure to an environmental neurotoxicant hastens the onset of amyotrophic lateral sclerosis-like phenotype in human Cu2+/Zn2+ superoxide dismutase 1 G93A mice: glutamate-mediated excitotoxicity. J Pharmacol Exp Ther (2011) 0.79
Arylazanylpyrazolone derivatives as inhibitors of mutant superoxide dismutase 1 dependent protein aggregation for the treatment of amyotrophic lateral sclerosis. J Med Chem (2013) 0.78
Proteasome activation is a mechanism for pyrazolone small molecules displaying therapeutic potential in amyotrophic lateral sclerosis. ACS Chem Neurosci (2014) 0.78
Screening of Drugs Inhibiting In vitro Oligomerization of Cu/Zn-Superoxide Dismutase with a Mutation Causing Amyotrophic Lateral Sclerosis. Front Mol Biosci (2016) 0.77
The preclinical discovery of amyotrophic lateral sclerosis drugs. Expert Opin Drug Discov (2011) 0.76
Tertiary Amine Pyrazolones and Their Salts as Inhibitors of Mutant Superoxide Dismutase 1-Dependent Protein Aggregation for the Treatment of Amyotrophic Lateral Sclerosis. J Med Chem (2015) 0.76
Deuteration and fluorination of 1,3-bis(2-phenylethyl)pyrimidine-2,4,6(1H,3H,5H)-trione to improve its pharmacokinetic properties. Bioorg Med Chem Lett (2014) 0.75
High Content Analysis in Amyotrophic Lateral Sclerosis. Mol Cell Neurosci (2016) 0.75
A computational-combinatorial approach identifies a protein inhibitor of superoxide dismutase 1 misfolding, aggregation, and cytotoxicity. J Biol Chem (2017) 0.75
A call for transparent reporting to optimize the predictive value of preclinical research. Nature (2012) 14.63
Adapting proteostasis for disease intervention. Science (2008) 13.22
Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science (2006) 5.39
Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem (2009) 5.23
Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science (2009) 4.80
Heat shock factors: integrators of cell stress, development and lifespan. Nat Rev Mol Cell Biol (2010) 4.63
Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. Mol Biol Cell (2003) 4.63
The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A (2002) 4.25
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging. Proc Natl Acad Sci U S A (2009) 3.44
Heat shock response modulators as therapeutic tools for diseases of protein conformation. J Biol Chem (2005) 2.95
YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst (2003) 2.91
Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A (2004) 2.89
Regulation of the cellular heat shock response in Caenorhabditis elegans by thermosensory neurons. Science (2008) 2.59
Chaperoning signaling pathways: molecular chaperones as stress-sensing 'heat shock' proteins. J Cell Sci (2002) 2.58
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Molecular chaperones and the stress of oncogenesis. Oncogene (2004) 2.51
Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem (2004) 2.45
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state. Nat Cell Biol (2006) 2.37
Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J (2004) 2.24
Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A (2003) 2.21
Polyglutamine protein aggregates are dynamic. Nat Cell Biol (2002) 2.21
A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell (2013) 2.14
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci U S A (2003) 2.05
The biology of proteostasis in aging and disease. Annu Rev Biochem (2015) 1.96
Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp Neurol (2005) 1.95
Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci U S A (2003) 1.92
Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci (2002) 1.92
Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem (2005) 1.91
Triptolide, an inhibitor of the human heat shock response that enhances stress-induced cell death. J Biol Chem (2006) 1.91
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.89
ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc Natl Acad Sci U S A (2006) 1.82
Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J Clin Invest (2011) 1.79
Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A (2011) 1.76
Structural properties and neuronal toxicity of amyotrophic lateral sclerosis-associated Cu/Zn superoxide dismutase 1 aggregates. J Cell Biol (2005) 1.74
Sp1 and Sp3 are oxidative stress-inducible, antideath transcription factors in cortical neurons. J Neurosci (2003) 1.72
Activation of heat shock and antioxidant responses by the natural product celastrol: transcriptional signatures of a thiol-targeted molecule. Mol Biol Cell (2008) 1.69
Regulation of organismal proteostasis by transcellular chaperone signaling. Cell (2013) 1.66
Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J Neurosci (2006) 1.65
Small-molecule proteostasis regulators for protein conformational diseases. Nat Chem Biol (2011) 1.64
Metazoan Hsp70 machines use Hsp110 to power protein disaggregation. EMBO J (2012) 1.62
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
In vivo binding of active heat shock transcription factor 1 to human chromosome 9 heterochromatin during stress. J Cell Biol (2002) 1.59
Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci (2004) 1.58
Selective neuronal nitric oxide synthase inhibitors and the prevention of cerebral palsy. Ann Neurol (2009) 1.58
Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. PLoS Genet (2009) 1.56
Analogues of 2-aminopyridine-based selective inhibitors of neuronal nitric oxide synthase with increased bioavailability. Bioorg Med Chem (2009) 1.49
Caenorhabditis elegans OSR-1 regulates behavioral and physiological responses to hyperosmotic environments. Genetics (2004) 1.49
Protein homeostasis in models of aging and age-related conformational disease. Adv Exp Med Biol (2010) 1.48
The stress of protein misfolding: from single cells to multicellular organisms. Cold Spring Harb Perspect Biol (2011) 1.48
Minimal pharmacophoric elements and fragment hopping, an approach directed at molecular diversity and isozyme selectivity. Design of selective neuronal nitric oxide synthase inhibitors. J Am Chem Soc (2008) 1.47
Malfolded protein structure and proteostasis in lung diseases. Am J Respir Crit Care Med (2014) 1.47
Neuronal circuitry regulates the response of Caenorhabditis elegans to misfolded proteins. Proc Natl Acad Sci U S A (2011) 1.46
Huntingtin and mutant SOD1 form aggregate structures with distinct molecular properties in human cells. J Biol Chem (2005) 1.46
Unexpected binding modes of nitric oxide synthase inhibitors effective in the prevention of a cerebral palsy phenotype in an animal model. J Am Chem Soc (2010) 1.45
Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. Nat Struct Mol Biol (2003) 1.45
Neuronal signaling modulates protein homeostasis in Caenorhabditis elegans post-synaptic muscle cells. Genes Dev (2007) 1.43
Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proc Natl Acad Sci U S A (2005) 1.42
Chaperone networks: tipping the balance in protein folding diseases. Neurobiol Dis (2010) 1.42
Structures of gamma-aminobutyric acid (GABA) aminotransferase, a pyridoxal 5'-phosphate, and [2Fe-2S] cluster-containing enzyme, complexed with gamma-ethynyl-GABA and with the antiepilepsy drug vigabatrin. J Biol Chem (2003) 1.40
The nascent polypeptide-associated complex is a key regulator of proteostasis. EMBO J (2013) 1.40
Revisiting heme mechanisms. A perspective on the mechanisms of nitric oxide synthase (NOS), Heme oxygenase (HO), and cytochrome P450s (CYP450s). Biochemistry (2008) 1.38
Discovery of highly potent and selective inhibitors of neuronal nitric oxide synthase by fragment hopping. J Med Chem (2009) 1.37
Integrating the stress response: lessons for neurodegenerative diseases from C. elegans. Trends Cell Biol (2008) 1.36
In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Genet (2010) 1.34
Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J Neurochem (2004) 1.33
Inhibition of translation and induction of apoptosis by Bunyaviral nonstructural proteins bearing sequence similarity to reaper. Mol Biol Cell (2003) 1.32
Huntington's disease: underlying molecular mechanisms and emerging concepts. Trends Biochem Sci (2013) 1.31
Exploration of the active site of neuronal nitric oxide synthase by the design and synthesis of pyrrolidinomethyl 2-aminopyridine derivatives. J Med Chem (2010) 1.31
The stress of misfolded proteins: C. elegans models for neurodegenerative disease and aging. Adv Exp Med Biol (2007) 1.30
Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiol Dis (2005) 1.30
Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J Biol Chem (2005) 1.25
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem (2009) 1.22
Pyrimidine-2,4,6-trione derivatives and their inhibition of mutant SOD1-dependent protein aggregation. Toward a treatment for amyotrophic lateral sclerosis. J Med Chem (2011) 1.22
Sp1 is up-regulated in cellular and transgenic models of Huntington disease, and its reduction is neuroprotective. J Biol Chem (2006) 1.21
Adenosine kinase inhibition selectively promotes rodent and porcine islet β-cell replication. Proc Natl Acad Sci U S A (2012) 1.21
Potent and selective neuronal nitric oxide synthase inhibitors with improved cellular permeability. Bioorg Med Chem Lett (2009) 1.21
Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochim Biophys Acta (2006) 1.21
Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep (2013) 1.20
Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem (2003) 1.20
CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nat Commun (2012) 1.20
N-methylsansalvamide a peptide analogues. Potent new antitumor agents. J Med Chem (2005) 1.19
The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models. Cell Rep (2012) 1.19
A genetic screening strategy identifies novel regulators of the proteostasis network. PLoS Genet (2011) 1.19
Inhibitors of cytochrome c release with therapeutic potential for Huntington's disease. J Neurosci (2008) 1.17
Selective neuronal nitric oxide synthase inhibitors. Curr Top Med Chem (2005) 1.17